← Back to Search

Procedure

EBUS-TBNA for Lung Cancer

N/A
Recruiting
Led By Kazuhiro Yasufuku, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Performance status score (WHO/ECOG) of 0-2
Medically inoperable for surgical resection
Must not have
Active systemic, pulmonary, or pericardial infection
Inability to give informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial reports that a less invasive but effective treatment, stereotactic body radiation therapy (SBRT), is well-tolerated for early stage lung cancer in medically inoperable patients.

Who is the study for?
This trial is for adults over 18 with confirmed non-small cell lung cancer who can't have surgery or chose not to. They should be in fair health (performance status 0-2), have early-stage T1-2 disease without distant metastasis, and need EBUS-TBNA staging before SBRT treatment. Pregnant women, those unfit for bronchoscopy, or planning other treatments are excluded.
What is being tested?
The trial tests the use of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) for lymph node staging in patients with lung cancer who will undergo Stereotactic Body Radiotherapy (SBRT). It aims to provide a less invasive option for accurate diagnosis and treatment planning.
What are the potential side effects?
While specific side effects aren't listed here, EBUS-TBNA is generally considered minimally invasive with potential risks like minor bleeding, infection risk at the needle site, and discomfort similar to other bronchoscopy procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
Select...
I cannot undergo surgery for my condition.
Select...
I am 18 years old or older.
Select...
My cancer is confirmed as non-small cell lung cancer through testing.
Select...
My cancer is in an early stage and hasn't spread far.
Select...
I have chosen not to undergo surgery for my condition.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I currently have an infection in my body, lungs, or around my heart.
Select...
I am unable to understand and agree to the study's details.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To test whether or not there is a difference in accuracy between CT/PET and the minimally invasive technique of EBUS-TBNA for mediastinal staging in patients with non-small cell lung cancer prior to stereotactic body radiotherapy (SBRT).

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: EBUS-TBNAExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EBUS-TBNA
2013
Completed Phase 4
~820

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,521 Previous Clinical Trials
503,154 Total Patients Enrolled
Kazuhiro Yasufuku, MDPrincipal InvestigatorUHN
3 Previous Clinical Trials
431 Total Patients Enrolled

Media Library

EBUS-TBNA (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT01786590 — N/A
Lung Cancer Research Study Groups: EBUS-TBNA
Lung Cancer Clinical Trial 2023: EBUS-TBNA Highlights & Side Effects. Trial Name: NCT01786590 — N/A
EBUS-TBNA (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01786590 — N/A
~0 spots leftby Dec 2024